资讯

Zacks Investment Research on MSN1 小时
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
GE HealthCare Technologies Inc. GEHC has received the FDA’s approval for an updated label for its positron emission ...
Medical Device Network4 小时
GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion
The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.
Commentary: Early diagnosis, real risks and new hope in Alzheimer's care
Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...
GE HealthCare Gets Approval to Expand Vizamyl Use for Dementia
The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...
Kalkine Media12 小时
GE HealthCare : FDA Expands Vizamyl Approval To Broaden Alzheimer's Diagnostic Capabilities
GE HealthCare (GEHC) announced that the U.S. Food and Drug Administration has approved an updated label for its positron emission tomography or PET imaging agent Vizamyl (flutemetamol F 18 injection) ...
The Eagle-Tribune21 小时
FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta ...
FDA Approves Expanded Indications for GE HealthCare’s Vizamyl PET Imaging Agent for Beta Amyloid Detection, Enabling More Precise Care for Alzheimer’s Patients ...
PMLive3 小时
New Alzheimer’s Treatments Are Driving a Shift in Earlier Detection and Clinician ...
June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.